Treatment with PCSK9 inhibitors reduces atherogenic VLDL remnants in a real-world study

Published 2019 View Full Article

  1. Home
  2. Publications
  3. Publication Search
  4. Publication Details
Title
Treatment with PCSK9 inhibitors reduces atherogenic VLDL remnants in a real-world study
Authors
Keywords
PCSK9 inhibitor, Evolocumab, Alirocumab, Lipoproteins, VLDL remnants
Journal
VASCULAR PHARMACOLOGY
Volume -, Issue -, Pages -
Publisher
Elsevier BV
Online
2019-03-23
DOI
10.1016/j.vph.2019.03.002

Ask authors/readers for more resources

Protocol

Community support

Reagent

Community support

Reprint

Contact the author

Discover Peeref hubs

Discuss science. Find collaborators. Network.

Join a conversation

Publish scientific posters with Peeref

Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.

Learn More
Webinars Posters Questions Hubs Funding Journals Articles Connect Collections Reviewers About Us FAQs Mobile App Privacy Policy Terms of Use
© Peeref 2019-2024. All rights reserved.